Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

Revenue projections:

Revenue projections for SUVENPHAR
Revenue projections for SUVENPHAR

Investors may react cautiously to news that SUVENPHAR's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 56.269436
debtToEquity 1.945000
earningsGrowth 0.755000
revenueGrowth 0.397000
grossMargins 0.627760
operatingMargins 0.316950
trailingEps 10.900000
forwardEps 0.000000

With SUVENPHAR's forward PE ratio being elevated, the stock may see limited price appreciation and face correction risks. It's essential to assess this metric alongside other fundamentals to determine the sustainability of the stock's current valuation.
SUVENPHAR's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.
Suven Pharmaceuticals Limited's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.

Price projections:

Price projections for SUVENPHAR
Price projections for SUVENPHAR

The current price of SUVENPHAR aligns with projections, showing no clear risks or opportunities. This lack of volatility suggests a stable environment for investors, who may wish to hold off on major adjustments until market conditions change.

Recommendation changes over time:

Recommendations trend for SUVENPHAR
Recommendations trend for SUVENPHAR


Analysts have shown a buy bias for Suven Pharmaceuticals Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Suven Pharmaceuticals Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.